Logo image
Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study
Journal article   Open access   Peer reviewed

Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study

Luis Felipe Reyes, Esteban Garcia-Gallo, Srinivas Murthy, Yuli V. Fuentes, Cristian C. Serrano, Elsa D. Ibáñez-Prada, James Lee, Amanda Rojek, Barbara Wanjiru Citarella, Bronner P. Gonçalves, …
Journal of Critical Care, Vol.77
2023

Abstract

Cardiovascular Diseases COVID-19 Female Humans Male Observational Studies as Topic Prospective Studies Risk Factors World Health Organization brain natriuretic peptide creatinine troponin adult aged Article artificial ventilation clinical outcome cohort analysis coronary angiography coronavirus disease 2019 cumulative incidence diastolic blood pressure echocardiography electrocardiography female follow up hospital mortality hospitalization human leukocyte count major adverse cardiac event major clinical study male mortality multicenter study myocardial disease observational study outcome assessment prospective study risk factor urea nitrogen blood level World Health Organization cardiovascular disease World Health Organization
Purpose: To determine its cumulative incidence, identify the risk factors associated with Major Adverse Cardiovascular Events (MACE) development, and its impact clinical outcomes. Materials and methods: This multinational, multicentre, prospective cohort study from the ISARIC database. We used bivariate and multivariate logistic regressions to explore the risk factors related to MACE development and determine its impact on 28-day and 90-day mortality. Results: 49,479 patients were included. Most were male 63.5% (31,441/49,479) and from high-income countries (84.4% [42,774/49,479]); however, >6000 patients were registered in low-and-middle-income countries. MACE cumulative incidence during their hospital stay was 17.8% (8829/49,479). The main risk factors independently associated with the development of MACE were older age, chronic kidney disease or cardiovascular disease, smoking history, and requirement of vasopressors or invasive mechanical ventilation at admission. The overall 28-day and 90-day mortality were higher among patients who developed MACE than those who did not (63.1% [5573/8829] vs. 35.6% [14,487/40,650] p < 0.001; 69.9% [6169/8829] vs. 37.8% [15,372/40,650] p < 0.001, respectively). After adjusting for confounders, MACE remained independently associated with higher 28-day and 90-day mortality (Odds Ratio [95% CI], 1.36 [1.33–1.39];1.47 [1.43–1.50], respectively). Conclusions: Patients with severe COVID-19 frequently develop MACE, which is independently associated with worse clinical outcomes. © 2023 The Authors
url
https://doi.org/10.1016/j.jcrc.2023.154318View
Published (Version of record) Open

Metrics

5 Record Views

Details

Logo image